Janux Therapeutics Inc (JANX) Price & Analysis

Compare

485 Followers

JANX Stock Chart & Stats

$26.48

-$2.71(-4.69%)

At close: Jan 08 4:00 PM EST

$26.48

-$2.71(-4.69%)

Day’s Range― - ―

52-Week Range$21.73 - $71.71

Previous CloseN/A

Volume1.13M

Average Volume (3M)1.11M

Market Cap

$1.72B

Enterprise ValueN/A

Total Cash (Recent Filing)$988.99M

Total Debt (Recent Filing)$22.66M

Price to Earnings (P/E)―

Beta1.62

Next Earnings

Mar 06, 2026

EPS Estimate

-0.66

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.39

Shares Outstanding60,093,933

10 Day Avg. Volume1,377,031

30 Day Avg. Volume1,110,281

Financial Highlights & Ratios

PEG Ratio13.76

Price to Book (P/B)2.81

Price to Sales (P/S)271.80

P/FCF Ratio-65.15

Enterprise Value/Market Cap0.00

Enterprise Value/Revenue0.00

Enterprise Value/Gross ProfitN/A

Enterprise Value/Ebitda0.00

Forecast

1Y Price Target

$80.20

Price Target Upside202.87% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering14

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Clinical TrialsJanux plans to initiate additional Phase 1b expansion studies for JANX007, including combinations with androgen receptor inhibitors and monotherapy in various resistant mCRPC patients.

Market PotentialThe company is expanding its trials into earlier lines of treatment, which could significantly increase its market potential in the U.S.

Research And DevelopmentJanux has a number of preclinical pipeline updates, including a PSMA x CD28 Tumor Activated Immunomodulator and a TROP2 x CD3 Tumor Activated T Cell Engager, indicating a strong research and development focus.

Bears Say

CompetitionThe r/r mCRPC setting is highly competitive with multiple programs in the clinic with different mechanisms of action.

Financial PerformanceJANX reported a Q3 net loss of $24.3MM and cash of $989MM.

Investor SentimentSentiment has turned highly negative and most investors seem to assume the worst occurred with these unknowns.

Janux Therapeutics Inc News

Janux Therapeutics price target raised to $46 from $45 at Stifel

Stifel raised the firm’s price target on Janux Therapeutics (JANX) to $46 from $45 and keeps a Buy...

2d ago

JANX

Janux Therapeutics price target raised to $48 from $47 at Barclays

Barclays raised the firm’s price target on Janux Therapeutics (JANX) to $48 from $47 and keeps an Overweight...

2d ago

JANX

Janux Therapeutics reports Q3 EPS (39c), consensus (61c)

As of September 30, 2025, Janux reported cash and cash equivalents and short-term investments of $989.0 million, compared...

3d ago

JANX

Janux Therapeutics rumor highlighted in Betaville alert

The M&A-focused Betaville blog sent an alert to its subscribers related to a rumor regarding Janux Therapeutics (JANX),...

12d ago

JANX

BTIG biotech analyst holds an analyst/industry conference call

Biotech Analyst Zelin discusses JANX007 (Janux Therapeutics (JANX)) and the evolving prostate cancer landscape on an Analyst/Industry conference...

26d ago

JANX

Buy Rating for Janux Therapeutics: Promising Data and Strong Financial Position Highlight Growth Potential

William Blair analyst Matt Phipps has reiterated their bullish stance on JANX stock, giving a Buy rating yesterday....

2d ago

JANX

Janux Therapeutics Reports Strong Financial Position Amid Clinical Advancements

Janux Therapeutics, Inc. ( ($JANX) ) has released its Q3 earnings. Here is a breakdown of the information...

3d ago

JANX

Buy Rating on Janux Therapeutics Inc: Strong Financials and Promising Clinical Developments

TD Cowen analyst Marc Frahm has maintained their bullish stance on JANX stock, giving a Buy rating yesterday....

3d ago

JANX

Promising Pipeline and Strategic Developments Justify Buy Rating for Janux Therapeutics Inc.

Oliver McCammon, an analyst from LifeSci Capital, maintained the Buy rating on Janux Therapeutics Inc. The associated price...

3d ago

JANX

Janux Therapeutics Advances with Promising Study on JANX008 for Solid Tumor Treatment

Janux Therapeutics, Inc. (($JANX)) announced an update on their ongoing clinical study. Janux Therapeutics, Inc. is conducting a...

13d ago

JANX

Janux Therapeutics Advances Prostate Cancer Study with JANX007

Janux Therapeutics, Inc. (($JANX)) announced an update on their ongoing clinical study. Janux Therapeutics, Inc. is conducting a...

13d ago

JANX

Janux Therapeutics Announces Departure of Chief Strategy Officer

The latest update is out from Janux Therapeutics Inc ( ($JANX) ). Byron Robinson, Ph.D., previously a named...

2M ago

JANX

Janux Therapeutics initiated with an Overweight at Barclays

Barclays initiated coverage of Janux Therapeutics (JANX) with an Overweight rating and $47 price target Janux has shown...

2M ago

JANX

Janux Therapeutics initiated with an Overweight at Barclays

Barclays analyst Etzer Darout initiated coverage of Janux Therapeutics (JANX) with an Overweight rating and $47 price target...

2M ago

JANX

JANX FAQ

What was Janux Therapeutics Inc’s price range in the past 12 months?

Janux Therapeutics Inc lowest stock price was $21.73 and its highest was $71.71 in the past 12 months.

What is Janux Therapeutics Inc’s market cap?

Janux Therapeutics Inc’s market cap is $1.72B.

When is Janux Therapeutics Inc’s upcoming earnings report date?

Janux Therapeutics Inc’s upcoming earnings report date is Mar 06, 2026 which is in 117 days.

How were Janux Therapeutics Inc’s earnings last quarter?

Janux Therapeutics Inc released its earnings results on Nov 06, 2025. The company reported -$0.39 earnings per share for the quarter, beating the consensus estimate of -$0.612 by $0.222.

Is Janux Therapeutics Inc overvalued?

According to Wall Street analysts Janux Therapeutics Inc’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Janux Therapeutics Inc pay dividends?

Janux Therapeutics Inc does not currently pay dividends.

What is Janux Therapeutics Inc’s EPS estimate?

Janux Therapeutics Inc’s EPS estimate is -0.66.

How many shares outstanding does Janux Therapeutics Inc have?

Janux Therapeutics Inc has 60,093,933 shares outstanding.

What happened to Janux Therapeutics Inc’s price movement after its last earnings report?

Janux Therapeutics Inc reported an EPS of -$0.39 in its last earnings report, beating expectations of -$0.612. Following the earnings report the stock price went up 4.067%.

Which hedge fund is a major shareholder of Janux Therapeutics Inc?

Currently, no hedge funds are holding shares in JANX

Janux Therapeutics Inc Stock Smart Score

Underperform

Fundamentals

Return on Equity

-12.48%

Trailing 12-Months

Asset Growth

49.29%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Janux Therapeutics Inc

Janux Therapeutics Inc (JANX) is a biotechnology company focused on developing innovative immunotherapies for cancer treatment. The company utilizes its proprietary platform technology to create a new class of therapeutics designed to selectively activate the immune system against tumors. Janux specializes in the development of its product candidates that aim to enhance the body's ability to fight cancer while minimizing adverse effects on healthy tissues. The company is advancing several candidates through preclinical and clinical stages, targeting various types of cancers.

Janux Therapeutics Inc (JANX) Earnings & Revenues

Historic Earnings Reports

JANX Stock 12 Month Forecast

Average Price Target

$80.20

▲(202.87% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"21":"$21","66":"$66","111":"$111","156":"$156","201":"$201"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":200,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$200.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":80.2,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$80.20</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":42,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$42.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[21,66,111,156,201],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Feb<br/>2025","6":"May<br/>2025","9":"Aug<br/>2025","12":"Nov<br/>2025","25":"Nov<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,28.71,41.886153846153846,55.06230769230769,68.23846153846154,81.41461538461539,94.59076923076924,107.76692307692306,120.94307692307692,134.11923076923077,147.29538461538462,160.47153846153847,173.6476923076923,186.82384615384615,{"y":200,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,28.71,32.67076923076923,36.63153846153846,40.59230769230769,44.55307692307692,48.51384615384616,52.47461538461539,56.43538461538462,60.39615384615385,64.35692307692308,68.31769230769231,72.27846153846154,76.23923076923077,{"y":80.2,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,28.71,29.732307692307693,30.754615384615384,31.776923076923076,32.79923076923077,33.82153846153846,34.84384615384615,35.86615384615385,36.88846153846154,37.91076923076923,38.933076923076925,39.95538461538462,40.97769230769231,{"y":42,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":54.39,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":40.18,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":53.54,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":43.48,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":32.89,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":26.81,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":32.05,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":25.01,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":23.22,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 29,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":23.56,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":22.86,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 30,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":23.7,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 16, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":28.71,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >